Castle Biosciences, Inc.

NASDAQ:CSTL

Medical - Diagnostics & Research

Healthcare
$33.38 +0.20%

+$0.04 today

Market cap
$1.03B
Beta
1.02
P/E (TTM)
-47.3
EPS (TTM)
-$0.43
52W Low $14.59High $44.28

Volume 0.38M

Average 0.37M

CSTL Depreciation & Amortization

Non-cash asset write-downs added back to net income because no cash left the business.

Castle Biosciences, Inc.NASDAQ: CSTL

Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026

Depreciation & amortization declines year over year

Q1 FY2026 depreciation & amortization of $3.93M fell 86.8% year over year, behind the -64.8% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 4.0% from the prior quarter. Over 3 fiscal years it compounded at +57.0% a year.

Context

  • Depreciation & amortization amounted to 11.8% of revenue in FY2025, up 7.0 pp from a year earlier.
  • Depreciation & amortization increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -86.8% toward the trailing-twelve-month pace of -64.8%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$3.93M+4.0% QoQ
Last fiscal yearDec 2025
$40.77M+154.9% YoY
LTMMar 2026
$14.94M-64.8% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-86.8%——
1 year+154.9%——
3-year CAGR+57.0%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the cash flow

Latest · FY2025
40.77M USD
Year-over-year change
+154.9%
4-year CAGR
+86.0%

Depreciation & Amortization vs competitors

How CSTL compares with its peers on the latest reported figures

  • CSTL's LTM Mar 2026 depreciation & amortization of $14.94M is the 5th largest of the 8 companies compared; the peer median is $20.83M.
  • Its year-over-year change of -64.8% is the lowest of 8, against a peer median of -8.0%.
  • Depreciation & amortization amounts to 4.4% of revenue for CSTL, versus a peer median of 6.2%.
CSTL Competitors Peer median
Depreciation & Amortization for CSTL and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NEONeoGenomics, Inc.LTM Jun 2026$65.46M -8.0%-0.8%8.5%
MYGNMyriad Genetics, Inc.LTM Mar 2026$51.8M -13.5%+0.6%6.2%
GHGuardant Health, Inc.LTM Sep 2026$39.23M -2.3%+3.4%3.1%
VCYTVeracyte, Inc.LTM Jun 2026$20.83M -9.4%-6.2%3.7%
CSTLCastle Biosciences, Inc.LTM Mar 2026$14.94M -64.8%+57.0%4.4%
PSNLPersonalis, Inc.LTM Mar 2026$9.83M -8.1%+6.0%15.2%
MDXHMDxHealth S.A.FY2025$9.21M +14.5%+23.3%8.5%
BDSXBiodesix, Inc.LTM Mar 2026$5.58M +0.8%-1.4%5.8%
FRNMFreenome, Inc. Common stock—— ———
Peer median (excluding CSTL) $20.83M-8.0%+0.6%6.2%

Competitors are the stored peer set for CSTL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(31.29M)(67.14M)(57.47M)18.25M(24.16M)
Depreciation & Amortization3.41M10.54M12.33M16M40.77M
Deferred Income Tax(8.74M)(1.88M)(223K)1.4M(6.23M)
Stock-Based Compensation21.74M36.32M51.22M50.32M45.89M
Change in Working Capital(4.1M)(7K)(6.63M)(14.13M)13.6M
Accounts Receivables(4.63M)(6.22M)(14.93M)(12.64M)6.88M
Inventory327K(1.68M)(3.96M)(193K)(2.14M)
Accounts Payables(182K)582K5.71M(4.37M)3.08M
Other Working Capital384K7.31M6.56M3.08M5.79M
Other Non-Cash Items0(19.5M)(4.86M)(6.97M)(5.53M)
Operating Cash Flow(18.98M)(41.66M)(5.63M)64.87M64.35M
Capital Expenditures(3.48M)(5.63M)(13.62M)(28.33M)(36.02M)
Acquisitions (Net)(63.18M)(26.97M)018K(18.73M)
Purchases of Investments0(134.69M)(189.08M)(205.73M)(188.71M)
Sales of Investments00186.5M183.9M190.73M
Other Investing Activities10K742K13K0(7.64M)
Investing Cash Flow(66.66M)(166.55M)(16.18M)(50.14M)(60.37M)
Debt Repayment(8K)(122K)(142K)9.9M(115K)
Common Stock Issued0002.02M2.21M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities5.43M1.64M(2.16M)(5.78M)(9.05M)
Financing Cash Flow5.42M1.52M(2.3M)6.14M(6.96M)
Effect of Forex Changes00000
Net Change in Cash(80.22M)(206.69M)(24.11M)20.87M(2.98M)
Free Cash Flow(22.47M)(47.29M)(19.25M)36.54M28.33M

Castle Biosciences, Inc.

NASDAQ:CSTL

Intrinsic Alpha fair value

Locked

Current Price

$33.38

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.